Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Article
  • Cited by 80

  • Get access
    Add to cart USD35.00
    Check if you have access via personal or institutional login
    Log in Register

Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus: Does Mupirocin Remain Effective?

  • Elaine S. Walker (a1), Jose E. Vasquez (a1), Roy Dula (a1), Hollie Bullock (a1) and Felix A. Sarubbi (a1)...

Abstract

Objective:

To determine the efficacy of mupirocin ointment in reducing nasal colonization with mupirocin-susceptible, methicillin-resistant Staphylococcus aureus (MS MRSA) as well as mupirocin-resistant MRSA (MR MRSA).

Design:

Prospective evaluation in which patients colonized with MRSA were treated twice daily with 2% topical mupirocin ointment for 5 days.

Setting:

James H. Quillen Veterans' Affairs Medical Center.

Patients:

Forty hospitalized patients with two anterior nares cultures positive for MRSA within a 7-day period.

Methods:

Treated patients had post-treatment cultures at day 3 and weeks 1,2, and 4. Isolates underwent mupirocin-susceptibility testing and DNA typing. MRSA clearance and type turnover were assessed for isolates that were mupirocin-susceptible, low-level (LL) MR MRSA and high-level (HL) MR MRSA.

Results:

Post-treatment nares cultures on day 3 were negative for 78.5%, 80%, and 27.7% of patients with MS MRSA, LL-MR MRSA, and HL-MR MRSA, respectively. Sustained culture negativity at 1 to 4 weeks was more common in the MS MRSA group (91%) than in the LL-MR MRSA group (25%) or the HL-MR MRSA group (25%). Positive post-treatment cultures usually showed the same DNA pattern relative to baseline. Plasmid curing of 18 HL-MR MRSA resulted in 15 MS MRSA and 3 LL-MR MRSA.

Conclusions:

Mupirocin was effective in eradicating MS MRSA, but strains of MR MRSA often persisted after treatment. This appeared to reflect treatment failure rather than exogenous recolonization. MR MRSA is now more prevalent and it is appropriate to sample MRSA populations for mupirocin susceptibility prior to incorporating mupirocin into infection control programs.

Copyright

COPYRIGHT: © The Society for Healthcare Epidemiology of America 2003

Corresponding author

Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614

References

Hide All
1.Boyce, JM. Methicillin-resistant Staphylococcus aureus in hospitals and long-term care facilities: microbiology, epidemiology, and preventive measures. Infect Control Hosp Epidemiol 1992;13:725–737.
2.Muder, RR, Brennen, C, Wagener, MM, et al.Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med 1991;114:107–112.
3.Spindel, SJ, Strausbaugh, LJ, Jacobson, C. Infections caused by Staphylococcus aureus in a Veterans' Affairs nursing home care unit: a 5-year experience. Infect Control Hosp Epidemiol 1995;16:217–223.
4.Nicolle, LE, Dyck, B, Thompson, G, et al.Regional dissemination and control of epidemic methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 1999;20:202–205.
5.Meier, PA, Carter, CD, Wallace, SE, Hollis, RJ, Pfaller, MA, Herwaldt, LA. A prolonged outbreak of methicillin-resistant Staphylococcus aureus in the burn unit of a tertiary medical center. Infect Control Hosp Epidemiol 1996;17:798–802.
6.Murray-Leisure, KA, Geib, S, Graceley, D, et al.Control of epidemic methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 1990;11:343–350.
7.Girou, E, Pujade, G, Legrand, P, Cizeau, F, Brun-Buisson, C.Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin Infect Dis 1998;27:543–550.
8.Kotilainen, P, Routamaa, M, Peltonen, R, et al.Eradication of methicillin-resistant Staphylococcus aureus from a health center ward and associated nursing home. Arch Intern Med 2001;161:859–863.
9.Arnold, MS, Dempsey, JM, Fishman, M, McAuley, PJ, Tibert, C, Vallande, NC. The best hospital practices for controlling methicillin-resistant Staphylococcus aureus: the cutting edge. Infect Control Hosp Epidemiol 2002;23:69–76.
10.Farr, BM, Jarvis, WR. Would active surveillance cultures help control healthcare-related methicillin-resistant Staphylococcus aureus infections? Infect Control Hosp Epidemiol 2002;23:65–68.
11.Barrett, SP. The value of nasal mupirocin in containing an outbreak of methicillin-resistant Staphylococcus aureus in an orthopaedic unit. J Hosp Infect 1990;15:137–142.
12.Cimochowski, GE, Harostock, MD, Brown, R, Bernardi, M, Alonzo, N, Coyle, K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001;71:1572–1579.
13.Kluytmans, JA, Mouton, JW, VandenBergh, MFQ, et al.Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996;17:780–785.
14.Eltringham, I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1997;35:1–8.
15.Cookson, BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 1998;41:11–18.
16.Watanabe, H, Masaki, H, Asoh, N, et al.Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect 2001;47:294–300.
17.Vasquez, JE, Walker, ES, Franzus, BW, Overbay, BK, Reagan, DR, Sarubbi, FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 2000;21:459–464.
18.Bradley, SF, Ramsey, MA, Morton, TM, Kauffman, CA. Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 1995;16:354–358.
19.Miller, MA, Dascal, A, Portnoy, J, Mendelson, J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996;17:811–813.
20.dos Santos, KRN, Fonseca, LS, Filho, PPG. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996;17:813–816.
21.Harbarth, S, Dharan, S, Liassine, N, Herrault, P, Auckenthaler, R, Pittet, D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1412–1416.
22.Gilbart, J, Perry, CR, Slocombe, B. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother 1993;37:32–38.
23.Kauffman, CA, Terpenning, MS, He, X, et al.Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term care facility with the use of mupirocin ointment. Am J Med 1993;94:371–378.
24.Semret, M, Miller, MA. Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains. Infect Control Hosp Epidemiol 2001;22:578–580.
25.Fuchs, PC, Jones, RN, Barry, AL. Interpretive criteria for disk-diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol 1990;28:608–609.
26.Maslow, JN, Slutsky, AM, Arbeit, RD. Application of pulsed-field electrophoresis to molecular epidemiology. In: Persing, DH, Smith, TF, White, TJ, eds. Diagnostic Molecular Microbiology Principles and Practice. Washington, DC: American Society for Microbiology; 1993:563–572.
27.Tenover, FC, Arbeit, RD, Goering, RV, et al.Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233–2239.
28.Rahman, M, Noble, WC, Cookson, B. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:387.
29.Rahman, M, Noble, WC, Cookson, B. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiol Infect 1989;102:261–270.
30.Kavi, J, Andrews, JM, Wise, R. Mupirocin-resistant Staphylococcus aureus. Lancet 1987;2:1472.
31.Fujimura, S, Watanabe, ABeighton, D. Characterization of the mup A gene in strains of methicillin-resistant Staphylococcus aureus with a low level of resistance to mupirocin. Antimicrob Agents Chemother 2001;45:641–642.
32.Layton, MC, Patterson, JE. Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital. Antimicrob Agents Chemother 1994;38:1664–1667.
33.Smith, GE, Kennedy, CC. Staphylococcus aureus resistant to mupirocin. J Antimicrob Chemother 1988;21:141–142.
34.Mulligan, ME, Murray-Leisure, KA, Ribner, BS, et al.Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993;94:313–328.
35.Bradley, SF. Effectiveness of mupirocin in the control of methicillin-resistant Staphylococcus aureus. Infections in Medicine 1993;10:23–31.
36.Muder, RR. Mupirocin and MRSA: current status. Infections in Medicine 1993;10:21–22.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed